ScholarIQanswers from OpenAlex & ORCID
Mukta Arora
ResearcherPublications, citations & collaboration network
Mukta Arora is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Mukta Arora have?
ScholarIQindexed works
Mukta Arora has 422 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mukta Arora have?
ScholarIQcitation count
Mukta Arora has 18,370 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Mukta Arora?
ScholarIQh-index
Mukta Arora has an h-index of 59 in OpenAlex.
What is the i10-index of Mukta Arora?
ScholarIQi10-index
Mukta Arora has an i10-index of 167 in OpenAlex.
What is the ORCID of Mukta Arora?
ScholarIQorcid
The ORCID for Mukta Arora is on the source record.
What is the OpenAlex record for Mukta Arora?
ScholarIQopenalex
The OpenAlex for Mukta Arora is on the source record.
What are the most-cited papers on Mukta Arora?
ScholarIQmost cited works
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Madan Jagasia, Hildegard Greinix, Mukta Arora, Kirsten M. Williams, Daniel Wolff, Edward W. Cowen, Jeanne Palmer, Daniel J. Weisdorf, Nathaniel S. Treister, Guang‐Shing Cheng, Holly Kerr, Pamela Stratton, Rafael F. Duarte, George B. McDonald, Yoshihiro Inamoto, Afonso Celso Vigorito, Sally Arai, Manuel B. Datiles, David A. Jacobsohn, Theo Heller, Carrie L. Kitko, Sandra A. Mitchell, Paul J. Martin, Howard M. Shulman, Roy S. Wu, Corey Cutler, Georgia B. Vogelsang, Stephanie J. Lee, Steven Z. Pavletic, Mary E.D. Flowers
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
Anita D’Souza, Caitrin Fretham, Stephanie J. Lee, Mukta Arora, Janet Brunner, Saurabh Chhabra, Steven M. Devine, Mary Eapen, Mehdi Hamadani, Parameswaran Hari, Marcelo C. Pasquini, Waleska S. Pérez, Rachel Phelan, Marcie Riches, J. Douglas Rizzo, Wael Saber, Bronwen E. Shaw, Stephen R. Spellman, Patricia Steinert, Daniel J. Weisdorf, Mary M. Horowitz
Risk factors for acute GVHD and survival after hematopoietic cell transplantation
Madan Jagasia, Mukta Arora, Mary E.D. Flowers, Nelson J. Chao, Philip L. McCarthy, Corey Cutler, Álvaro Urbano-Ispizúa, Steven Z. Pavletic, Michael Haagenson, Mei-Jie Zhang, Joseph H. Antin, Brian J. Bolwell, Christopher Bredeson, Jean‐Yves Cahn, Mitchell S. Cairo, Robert Peter Gale, Vikas Gupta, Stephanie J. Lee, Mark R. Litzow, Daniel J. Weisdorf, Mary M. Horowitz, Theresa Hahn
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
David B. Miklos, Corey Cutler, Mukta Arora, Edmund K. Waller, Madan Jagasia, Iskra Pusic, Mary E.D. Flowers, Aaron C. Logan, Ryotaro Nakamura, Bruce R. Blazar, Yunfeng Li, Stephen Chang, Indu Lal, Jason A. Dubovsky, Danelle F. James, Lori Styles, Samantha Jaglowski
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation
Shernan G. Holtan, Todd E. DeFor, Aleksandr Lazaryan, Nelli Bejanyan, Mukta Arora, Claudio G. Brunstein, Bruce R. Blazar, Margaret L. MacMillan, Daniel J. Weisdorf